Arcus Biosciences, Inc. (RCUS) Spending and interest coverage
- R&D / revenue · 12 months: Value 871.93%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 110.53%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 871.93% | Research and development expense / revenue. Period ending 2026-06-30. $497.00M ÷ $57.00M × 100 ≈ 871.93% |
| Stock-based compensation / revenue · 12 months | 110.53% | Share-based compensation / revenue. Period ending 2026-06-30. $63.00M ÷ $57.00M × 100 ≈ 110.53% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 497.00M USD | Research and Development Expense |
| Revenue | 57.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 63.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -486.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $497.00M | $57.00M | $63.00M | $-486.00M | (m) | 871.93% | 110.53% | (m) | (m) |
| 2026-03-31 | $523.00M | $32.00M | $63.00M | $-398.00M | (m) | 1634.38% | 196.88% | (m) | (m) |
| 2025-12-31 | $523.00M | $33.00M | $60.00M | $-386.00M | (m) | 1584.85% | 181.82% | (m) | (m) |
| 2025-09-30 | $503.00M | $45.00M | $62.00M | $-375.00M | (m) | 1117.78% | 137.78% | (m) | (m) |
| 2025-06-30 | $485.00M | $46.00M | $67.00M | $-338.00M | (m) | 1054.35% | 145.65% | (m) | (m) |
| 2025-03-31 | $461.00M | $49.00M | $72.00M | $-436.00M | (m) | 940.82% | 146.94% | (m) | (m) |
| 2024-12-31 | $448.00M | $51.00M | $76.00M | $-330.00M | (m) | 878.43% | 149.02% | (m) | (m) |
| 2024-09-30 | $440.00M | $263.00M | $77.00M | $-318.00M | (m) | 167.30% | 29.28% | (m) | (m) |
| 2024-06-30 | $399.00M | $247.00M | $76.00M | $-293.00M | (m) | 161.54% | 30.77% | (m) | (m) |
| 2024-03-31 | $368.00M | $237.00M | $74.00M | $-270.00M | (m) | 155.27% | 31.22% | (m) | (m) |
| 2023-12-31 | $340.00M | $117.00M | $73.00M | $-340.00M | (m) | 290.60% | 62.39% | (m) | (m) |
| 2023-09-30 | $327.00M | $120.00M | $72.00M | $-323.00M | (m) | 272.50% | 60.00% | (m) | (m) |
| 2023-06-30 | $322.00M | $121.00M | $70.00M | $-313.00M | (m) | 266.12% | 57.85% | (m) | (m) |
| 2023-03-31 | $308.00M | $119.00M | $67.00M | $-299.00M | (m) | 258.82% | 56.30% | (m) | (m) |
| 2022-12-31 | $288.00M | $112.00M | $65.00M | $-280.00M | (m) | 257.14% | 58.04% | (m) | (m) |
| 2022-09-30 | $257.74M | $432.84M | $62.29M | $75.71M | (m) | 59.54% | 14.39% | (m) | (m) |
| 2022-06-30 | $252.31M | $408.72M | $60.62M | $66.97M | (m) | 61.73% | 14.83% | (m) | (m) |
| 2022-03-31 | $251.17M | $391.43M | $58.31M | $59.81M | (m) | 64.17% | 14.90% | (m) | (m) |
| 2021-12-31 | $256.35M | $382.88M | $54.53M | $54.25M | (m) | 66.95% | 14.24% | (m) | (m) |
| 2021-09-30 | $255.12M | $37.87M | $48.60M | $-279.03M | (m) | 673.68% | 128.34% | (m) | (m) |
| 2021-06-30 | $235.67M | $92.94M | $40.02M | $-199.34M | (m) | 253.58% | 43.06% | (m) | (m) |
| 2021-03-31 | $202.59M | $85.23M | $31.12M | $-168.58M | (m) | 237.71% | 36.52% | (m) | (m) |
| 2020-12-31 | $159.35M | $77.52M | $21.82M | $-124.23M | (m) | 205.57% | 28.16% | (m) | (m) |
| 2020-09-30 | $131.32M | $77.78M | $16.37M | $-89.75M | (m) | 168.84% | 21.05% | (m) | (m) |
| 2020-06-30 | $96.76M | $15.00M | $13.11M | $-114.55M | (m) | 645.09% | 87.39% | (m) | (m) |
| 2020-03-31 | $86.07M | $15.00M | $10.77M | $-98.34M | (m) | 573.79% | 71.79% | (m) | (m) |
| 2019-12-31 | $78.48M | $15.00M | $8.98M | $-88.71M | (m) | 523.21% | 59.87% | (m) | (m) |
| 2019-09-30 | $69.23M | $6.81M | $7.60M | $-84.67M | (m) | 1016.31% | 111.54% | (m) | (m) |
| 2019-06-30 | $64.85M | $9.35M | $5.91M | $-73.56M | (m) | 693.33% | 63.15% | (m) | (m) |
| 2019-03-31 | $53.55M | $8.85M | $4.89M | $-60.30M | (m) | 604.86% | 55.26% | (m) | (m) |
| 2018-12-31 | $49.65M | $8.35M | $3.87M | $-54.86M | (m) | 594.35% | 46.38% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $47.22M | $1.41M | $495.00K | $-53.44M | (m) | 3341.68% | 35.03% | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $14.25M | (m) | $90.00K | $-18.18M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |